Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers

NCT04260802 is registered in ClinicalTrials.gov with Ocellaris Pharma, Inc. as lead sponsor.

NCT NCT04260802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04260802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
Lead sponsor
Ocellaris Pharma, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
September 24, 2020
Completion date
November 7, 2025
Enrollment
73 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cancer, cervical cancer, gastric cancer, hepatocellular carcinoma, locally advanced malignant neoplasm, locally advanced solid tumor, merkel cell carcinoma, metastatic cancer, neoplasms, non small cell lung cancer, ovarian cancer, renal cell carcinoma, sarcoma, squamous cell carcinoma, squamous cell carcinoma of head and neck, triple negative breast cancer, urothelial carcinoma, urothelial neoplasm